TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

ANJESO

MELOXICAM
Approved 2020-02-20
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
6
Years on Market

Details

Status
Discontinued
First Approved
2020-02-20
Routes
INTRAVENOUS
Dosage Forms
SOLUTION

Companies

BAUDAX
Active Ingredient: MELOXICAM

ANJESO Approval History

Loading approval history...

What ANJESO Treats

1 FDA approvals

Originally approved for its first indication in 2020 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ANJESO FDA Label Details

Pro

ANJESO Patents & Exclusivity

Latest Patent: Mar 2039

Patents (5 active)

US11458145 Expires Mar 8, 2039
US10881663 Expires Mar 8, 2039
US10709713 Expires May 26, 2030
US11253478 Expires May 26, 2030
US9974746 Expires May 26, 2030
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA210583 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.